Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free BXP Stock Alerts

Beximco Pharmaceuticals (BXP) Competitors

Beximco Pharmaceuticals logo
Compare

BXP vs. BGSC, PRSR, PINE, DX, and SOHO

Should you buy Beximco Pharmaceuticals stock or one of its competitors? MarketBeat compares Beximco Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Beximco Pharmaceuticals include BMO Global Smaller Companies (BGSC), Prs Reit (PRSR), Pinewood Technologies Group (PINE), DX (Group) (DX), and Triple Point Social Housing REIT (SOHO). These companies are all part of the "trading" industry.

How does Beximco Pharmaceuticals compare to BMO Global Smaller Companies?

Beximco Pharmaceuticals (LON:BXP) and BMO Global Smaller Companies (LON:BGSC) are both small-cap trading companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Beximco Pharmaceuticals has higher revenue and earnings than BMO Global Smaller Companies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A
BMO Global Smaller Companies£303.85M0.00N/A£50.70N/A

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled BMO Global Smaller Companies'average media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
BMO Global Smaller Companies Neutral

Beximco Pharmaceuticals has a net margin of 16.57% compared to BMO Global Smaller Companies' net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 7.76% beat BMO Global Smaller Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.57% 7.76% 6.97%
BMO Global Smaller Companies N/A N/A N/A

Summary

Beximco Pharmaceuticals beats BMO Global Smaller Companies on 7 of the 8 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Prs Reit?

Beximco Pharmaceuticals (LON:BXP) and Prs Reit (LON:PRSR) are both small-cap trading companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Prs Reit has a net margin of 115.87% compared to Beximco Pharmaceuticals' net margin of 16.57%. Prs Reit's return on equity of 10.16% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.57% 7.76% 6.97%
Prs Reit 115.87%10.16%2.07%

Prs Reit has a consensus target price of GBX 115, suggesting a potential upside of 1.77%. Given Prs Reit's stronger consensus rating and higher probable upside, analysts plainly believe Prs Reit is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Prs Reit
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.4% of Prs Reit shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Prs Reit shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Beximco Pharmaceuticals has a beta of 0.251, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Prs Reit has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Beximco Pharmaceuticals has higher revenue and earnings than Prs Reit. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Prs Reit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A
Prs Reit£83.08M7.47£93.32M£14.008.07

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Prs Reit'saverage media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Prs Reit Neutral

Summary

Prs Reit beats Beximco Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Pinewood Technologies Group?

Pinewood Technologies Group (LON:PINE) and Beximco Pharmaceuticals (LON:BXP) are both small-cap trading companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Pinewood Technologies Group's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Pinewood Technologies Group Neutral
Beximco Pharmaceuticals Neutral

Pinewood Technologies Group has a net margin of 124.20% compared to Beximco Pharmaceuticals' net margin of 16.57%. Pinewood Technologies Group's return on equity of 35.39% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Pinewood Technologies Group124.20% 35.39% 4.17%
Beximco Pharmaceuticals 16.57%7.76%6.97%

15.4% of Pinewood Technologies Group shares are owned by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 41.5% of Pinewood Technologies Group shares are owned by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Beximco Pharmaceuticals has higher revenue and earnings than Pinewood Technologies Group. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Pinewood Technologies Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pinewood Technologies Group£40.50M8.67£45.24M£48.006.35
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A

Pinewood Technologies Group has a beta of 0.571, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.251, suggesting that its stock price is 75% less volatile than the broader market.

Pinewood Technologies Group presently has a consensus price target of GBX 585, indicating a potential upside of 91.83%. Given Pinewood Technologies Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pinewood Technologies Group is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pinewood Technologies Group
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Pinewood Technologies Group beats Beximco Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to DX (Group)?

DX (Group) (LON:DX) and Beximco Pharmaceuticals (LON:BXP) are both small-cap trading companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

DX (Group) has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.251, meaning that its share price is 75% less volatile than the broader market.

Beximco Pharmaceuticals has higher revenue and earnings than DX (Group).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DX (Group)£471.20M0.00£22.80M£0.04N/A
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A

In the previous week, DX (Group)'s average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
DX (Group) Neutral
Beximco Pharmaceuticals Neutral

Beximco Pharmaceuticals has a net margin of 16.57% compared to DX (Group)'s net margin of 4.84%. DX (Group)'s return on equity of 36.77% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
DX (Group)4.84% 36.77% 8.00%
Beximco Pharmaceuticals 16.57%7.76%6.97%

55.8% of DX (Group) shares are held by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 26.4% of DX (Group) shares are held by insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

DX (Group) beats Beximco Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Triple Point Social Housing REIT?

Triple Point Social Housing REIT (LON:SOHO) and Beximco Pharmaceuticals (LON:BXP) are both small-cap trading companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Triple Point Social Housing REIT presently has a consensus target price of GBX 82, suggesting a potential upside of 9.04%. Given Triple Point Social Housing REIT's stronger consensus rating and higher possible upside, equities research analysts plainly believe Triple Point Social Housing REIT is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Triple Point Social Housing REIT
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Beximco Pharmaceuticals has a net margin of 16.57% compared to Triple Point Social Housing REIT's net margin of 7.28%. Beximco Pharmaceuticals' return on equity of 7.76% beat Triple Point Social Housing REIT's return on equity.

Company Net Margins Return on Equity Return on Assets
Triple Point Social Housing REIT7.28% 0.80% 2.38%
Beximco Pharmaceuticals 16.57%7.76%6.97%

14.4% of Triple Point Social Housing REIT shares are owned by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 0.1% of Triple Point Social Housing REIT shares are owned by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Triple Point Social Housing REIT's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Triple Point Social Housing REIT Neutral
Beximco Pharmaceuticals Neutral

Triple Point Social Housing REIT has a beta of 0.464, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.251, indicating that its stock price is 75% less volatile than the broader market.

Beximco Pharmaceuticals has higher revenue and earnings than Triple Point Social Housing REIT. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Triple Point Social Housing REIT, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Triple Point Social Housing REIT£9.15M32.35£26.02M£0.7698.95
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousandN/A

Summary

Beximco Pharmaceuticals beats Triple Point Social Housing REIT on 7 of the 13 factors compared between the two stocks.

Get Beximco Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BXP vs. The Competition

Export
MetricBeximco PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£229.06M£6.52B£7.08B£3.00B
Dividend Yield6.46%2.83%2.68%6.17%
P/E Ratio0.035.0827.42368.17
Price / SalesN/A1,653.12527.9584,565.95
Price / CashN/A10.1848.4727.87
Price / BookN/A10.8510.887.69
Net Income£970.84B£20.27B£3.59B£5.89B
7 Day Performance9.24%-0.36%-0.26%-0.68%
1 Month PerformanceN/A-1.00%4.55%-1.01%
1 Year Performance28.43%9.82%29.86%61.81%

Beximco Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BXP
Beximco Pharmaceuticals
N/AN/AN/A+28.4%£229.06M£53.93B0.035,500
BGSC
BMO Global Smaller Companies
N/AN/AN/AN/A£769.56M£303.85M2.77N/A
PRSR
Prs Reit
3.1801 of 5 stars		GBX 113
flat		GBX 115
+1.8%		+6.2%£620.65M£83.08M8.072
PINE
Pinewood Technologies Group
2.6436 of 5 stars		GBX 304.50
+1.3%		GBX 585
+92.1%		-36.6%£331.48M£40.50M6.345,334
DX
DX (Group)
N/AN/AN/AN/A£306.77M£471.20M1,185.0020

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BXP) was last updated on 7/12/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Buy the “unseen winner of the AI race” before July 22
Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...
Chaikin Analytics | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel